Articles tagged with B Cell Lymphoma
A phase III study will evaluate Revlimid as a maintenance therapy for elderly patients with diffuse large B-cell lymphoma. The study aims to determine progression-free survival and overall survival associated with Revlimid compared to placebo.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a new three-drug combination therapy that spares patients from prolonged myelosuppression, a potentially lethal side effect of traditional treatments. The treatment achieved a remission rate of 96% in patients with indolent B cell lymphoma.
Researchers used FLT PET to monitor treatment response in DLBCL patients treated with R-CHOP chemotherapy. Treatment led to temporary increases in FLT uptake, indicating increased DNA synthesis and tumor cell proliferation. This suggests that FLT PET may be a sensitive tool for differentiating non-responding tumors.
Researchers found that mir-17-92 cluster microRNAs are overexpressed in most common cancers, including B-cell lymphoma and colorectal carcinomas. This overexpression may contribute to cancer development and progression.
Researchers have identified a set of six genes that correlate with survival in diffuse large B-cell lymphoma, including LMO2, BCL6, and CCND2. The findings suggest that molecular profiling may help refine prognoses for this difficult-to-treat blood cancer.
The study found that adding rituximab to the CHOP regimen as a first-line treatment did not significantly impact overall response rates or early disease progression. Maintenance rituximab showed promise in prolonging time-to-treatment failure, but had no effect on overall survival.
Researchers create animal model that develops three types of lymphoma, shedding light on genetic mutations and cell signal pathways. The discovery holds promise for developing new treatments to block cancer-causing signals.